Prostaglandin E1 Lipo combined with Shuxuetong superficial treatment of elderly diabetic foot ulcers.doc

 PAGE \* MERGEFORMAT 12 Prostaglandin E1 Lipo combined with Shuxuetong superficial treatment of elderly diabetic foot ulcers Study: Hou Min Bai Xiaoning Wang Huifang all [Abstract] Purpose prostaglandin E1 Lipo (Lipo PGE1) combined with Shuxuetong injection treatment of elderly diabetic foot (DF) superficial ulcer healing effect. Methods older patients with grade DF 1 86 patients, randomly divided into control and treatment group in the diet, insulin and superficial foot ulcers, based on regular exchange of dressing, the control group received Lipo PGE120 g intravenous normal saline 20 ml, 1 / d; treatment group based in the application of Lipo PGE1 , using Shuxuetong injection 8 ml 250 ml normal saline intravenously to join, 1 / d.4 w as a course of treatment. were observed femoral artery, popliteal artery, dorsalis pedis artery diameter (ID) and peak Blood flow velocity (VP) of change; tibial nerve, peroneal nerve sensory conduction velocity (SNCV) and motor conduction velocity (MNCV) changes; two hemorheology and blood lipid changes; determination of changes in ulcers and lower extremity symptoms observed improvement. Results ID and VP groups lower limb compared with before treatment significantly improved (P lt;0.05 or P lt;0.01), dorsalis pedis artery in treatment group ID, femoral artery and dorsalis pedis artery VP than before significant difference more obvious (P lt;0.01), and the treatment group dorsalis pedis artery ID and VP with the control group, the difference was significant (P lt;0.05); control group, tibial nerve, peroneal nerve SNCV and MNCV and treatment were significant differences (P lt; 0.05), but more significant differences between treatment groups (P lt;0.01); addition to the high-density lipoprotein cholesterol (HDL-C), the control group, the indicators of hemorheology and blood lipid and before treatment were significantly different (P lt;0.05 ), more significant differences between the treatment group (P lt;0.01), and the trea